Jeffrey A. Meyerhardt, MD, MPH
Associate Professor of Medicine, Harvard Medical School
Office phone: 617-632-6855
Preferred contact method: office phone
View Physician Profile
Area of ResearchDiet and Lifestyle Studies in Patients with Colorectal Cancer
Dana-Farber Cancer Institute
450 Brookline Avenue
Boston, MA 02215
BiographyDr. Meyerhardt received his MD from Yale School of Medicine in 1997. He completed a residency in internal medicine at Beth Israel Deaconness Medical Center, in Boston, followed by a medical oncology fellowship at DFCI. He joined the Gastointestinal Cancer Center at DFCI in 2002 and became an assistant professor of medicine at Harvard Medical School in 2004.
- Tisch Outstanding Achievement Award, 2004
- Irving Jancock Fellow, Dana-Farber Cancer Institute, 2002
ResearchDiet and Lifestyle Studies in Patients with Colorectal Cancer
We have a strong interest in the influence of diet and lifestyle on outcomes among patients with colorectal cancer. While much research has focused on the impact of host factors on the risk of developing colorectal cancer, little data are available to suggest how these factors impact on treatment-related toxicities or long-term outcomes among patients already diagnosed with the disease. Using databases from large oncology cooperative group trials, the Nurses Health Study, and Health Professionals Follow-up Study, we have analyzed the influence of diet and lifestyle on outcomes in early-stage colorectal cancer patients. We have been involved in studies of physical activity, diet, smoking, obesity, weight change, COX inhibitors and vitamin D in colorectal cancer survivors. Based on these studies, I am the principal investigator of a national randomized trial (CALGB 80702) that will test celecoxib as adjunctive therapy to standard treatment for stage III colon cancer. The trial is under development with the National Cancer Institute.
I serve as a Project co-Leader for the Gastrointestinal Cancer SPORE of Dana-Farber / Harvard Cancer Center. We are studying molecular pathways associated with sensitivity and resistance to monoclonal antibodies against the epidermal growth factor receptor for colorectal cancer.
Finally, I am involved in mid-stage testing of novel agents for colorectal cancer. I have served as the principal investigator and co-investigator on multiple phase I / II trials
- Jackson-Mccleary, Nadine